Creso Pharma (ASX:CPH) - Co Founder, Boaz Wachtel (left)
Co Founder, Boaz Wachtel (left)
Source: ABC
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Creso Pharma (CPH) has launched three new CBD-based tea products under its cannaQIX brand
  • These products are now available in Switzerland with additional European markets expected in the near-term
  • The company will also be looking to sell its products in Germany following a reversal of charges against hemp sellers in the country
  • These CBD-based teas include cannaQIX tea, cannaQIX NITE tea and cannaQIX Immunity tea, and they aim to reduce stress, enable better sleep and optimise well-being
  • Creso will use the technology that helped with the manufacturing of these teas for its flagship lozenge products
  • Creso is up 2.5 per cent on the market and shares are trading at 20.5 cents

Creso Pharma (CPH) has launched three new CBD-based tea products under its cannaQIX brand.

These products are now available in Switzerland with additional European markets expected in the near-term.

Following a recent decision by the German Federal Court of Justice to reverse charges against hemp tea sellers, Creso will be looking to launch its teas in Germany.

Upon a successful launch of its products in Switzerland and Germany, Creso will aim to expand its reach into other European countries.

These CBD-based teas include cannaQIX tea, cannaQIX NITE tea and cannaQIX Immunity tea.

Source: Creso Pharma

The cannaQIX tea is designed to help the management of stress, the cannaQIX NITE tea is to be consumed at night for a better sleep, while cannaQIX immunity tea optimises well-being.

Creso will use the technology that helped with the manufacturing of these teas for its flagship lozenge products.

“We are proud to have completed the finalisation of this ground-breaking technology for our new CBD tea products, which opens a number of new and globally applicable opportunities for Creso Pharma,” Commercial and Development Director Dr Gian Trepp said.

“The new products and formulation provide a very tasty CBD tea that will become a key component in the future production of the cannaQIX lozenges,” he added.

Creso is up 2.5 per cent on the market and shares are trading at 20.5 cents at 3:17 pm AEDT.

CPH by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…